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Breast Cancer Treatment
Basics for the Primary Care Provider
Sarah Hirsh/Cokenakes PGY2 
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Learning Objectives: 
1. To review the prevalence of breast cancer and the 
mortality rate of breast cancer in the United States. 
2. To understand breast cancer staging and its role in 
prognostication. 
3. To understand the therapies offered for the treatment of 
non-metastatic, invasive breast cancer and their side 
effects. 
4. To review the role of the PCP in caring for patients 
undergoing treatment for breast cancer and those in 
remission. 
Topics not addressed in this lecture: 
1. Routine breast cancer screening
2. Comprehensive management of breast cancer - this is an 
overview for the target audience of primary care 
providers. 
3. We will cover DCIS and discuss metastatic breast cancer 
briefly but will largely focus on non-metastatic invasive 
disease.  
Case #1: M.T. 
Case #1: M.T. 
67 y/o F from Liberia with PMH HTN presents to the E.D. on 
9/10/18 with a CC of “itchy right breast.” 
Ultrasound showed, “masslike lesion in the right breast 
incompletely evaluated on this study. Further evaluation 
with mammogram is recommended.” 
Case #1: M.T. 
9/13/18: Became this patient’s PCP, 
ordered diagnostic mammogram and 
biopsy.
9/20/18: Pathology back; invasive 
high grade carcinoma, ER-, PR-, 
ERBB2-
9/28/18: Seen for the first time by 
medical oncology for triple 
negative breast cancer.  
Case #1: M.T. 
10/3/18: CT CAP with metastatic disease involving the 
thoracic and lumbar spine. 
Patient seen several times over the course of the next 
months by medical oncology, but refused chemotherapy. 
Palliative radiation in November, 2018. 
12/27/18: Passed away on home hospice. 
Breast Cancer Epidemiology
Breast Cancer Prevalence in the U.S. 
➢ Approximately 300,000 new cases of breast cancer in the 
United States each year. 
➢ 1 out of every 8 women will have a diagnosis of breast 
cancer at some point in her life. 
Breast Cancer Mortality in the U.S.
Overall mortality from breast 
cancer has been declining over 
the past decades. 
Disparities in mortality remain 
apparent.  
Breast Cancer Risk Factors
Older age 
Female gender
Positive family history 
Genetic variants associated 
with breast cancer
Dense breast tissue
Hormone replacement therapy 
Prior radiation to the chest 
Breast Cancer Staging and Classification
DCIS
Stage 0 Breast Cancer
TNM Anatomic Staging
(T) = tumor size 
(N) = nodal involvement 
(M) = presence or 
absence of metastasis 



Prognostic Staging: Molecular Subtypes 
(PR+) = progesterone 
receptor positive
(ER+) = estrogen 
receptor positive 
(ERBB2+) = erb-B2 
receptor tyrosine 
kinase 2
Staging: Molecular Subtypes 
Terms used in this discussion: 
Non-invasive disease = Stage 0 = DCIS 
Early invasive disease = Stages I-II
Locally advanced disease = Stage III
Metastatic disease = Stage IV
5-year Survival by Stage 
Breast Cancer Stage 5-Year Breast Cancer Specific Survival 
Stage 0 95-100% 
Stage I 98-100% 
Stage II 90-99%
Stage III 66-98% 
Stage V ~27% 
Summary of Key 
Points: 
Staging and Classification
➢ DCIS, or Stage 0 breast 
cancer is non-invasive 
and confined to the 
ducts. It may progress 
to invasive disease. 
➢ Both TNM criteria and 
molecular markers drive 
prognostic staging.  
Breast Cancer Treatment 
Surgical 
Management
➢ Lumpectomy vs. 
mastectomy 
➢ Sentinel lymph node 
biopsy (SLNB) vs. 
axillary lymph node 
dissection (ALND) 
Surgical Management: Lumpectomy vs. Mastectomy 
Surgical Management: Lumpectomy vs. Mastectomy 
➢ Lumpectomy should be offered if “clean” margins can be 
achieved with good cosmetic effect. 
➢ In general, higher stage breast cancer may require 
greater surgical intervention. 
➢ Some patients may choose mastectomy > lumpectomy for 
reasons of comfort or access to radiation therapy. 
Surgical Management: SLNB vs. ALND
SLNB (above) involves the sampling of tissue 
from the first axillary nodes into which an 
injected tracer drains. 
ALND involves the removal of more lymph nodes, 
usually level 1 and 2 (right), and adipose 
tissue from the axilla. 
Surgical Management: SLNB vs. ALND
➢ SLNB is prefered for patients without clinical evidence 
of nodal disease and for those with early invasive breast 
cancer (usually fewer than 3 positive nodes) who plan to 
undergo lumpectomy. 
➢ ALDN is reserved for those who have positive nodes on 
SLNB and will undergo mastectomy or those with large, 
multicentric, high-grade tumors.  
Radiation therapy
Radiation Therapy 
➢ Goal of radiation following surgery is to eliminate 
remaining, subclinical disease 
➢ Recommended for those that undergo lumpectomy and for 
patients with high-risk, node-positive disease that has 
been treated with mastectomy. 
➢ Partial breast irradiation requires fewer radiation 
session and decreases acute skin toxicity 
Systemic Therapies
Preoperative/Postoperative
➢ Endocrine Therapy
➢ Chemotherapy 
➢ Immunotherapy 
Systemic Treatments: Endocrine Therapy 
➢ Approximately ⅔ of breast cancer are hormone receptor 
positive (ER+, PR+) and are therefore amenable to 
treatment with endocrine therapies. 
Systemic Treatments: Endocrine Therapy 
➢ Tamoxifen, a SERM, binds 
competitively to estrogen 
receptors, preventing the 
downstream transcription of 
estrogen-related genes. 
➢ Aromatase inhibitors inhibit the 
conversion of androgens to 
estrogens. 
Systemic Treatments: Endocrine Therapy 
Premenopausal at diagnosis: 
5 years Tamoxifen. 5 years AI only  
if high risk of recurrence.
Reevaluate: 
If still premenopausal, Tamoxifen 
for another 5 years.
If now postmenopausal, Tamoxifen or 
AI for another 5 years.    
Postmenopausal at diagnosis: 
10 years total of endocrine 
therapy. Can be Tamoxifen, AI or a 
sequence of the two medications. 
Systemic Treatment: Immunotherapy
➢ Approximately 15-20% of breast 
cancers overexpress ERBB2 and 
are amenable to treatment with 
monoclonal antibodies directed 
against this protein. 
➢ Trastuzumab is administered 
every 3 weeks for 1 year. 
➢ High risk ERBB+ breast cancer 
may benefit from additional 
pertuzumab (MAB) or neratinib 
(oral TKI). 
Systemic Treatment: Chemotherapy 
➢ Also used to treat hormone receptor positive and ERBB2+ 
breast cancer, but INTEGRAL to the treatment of triple 
negative breast cancer. 
➢ Taxane-based, non-anthracycline regimens are appropriate 
for lower risk disease. 
➢ Anthracyclines are usually included in regimens that 
target cancer with lymph node involvement and triple 
negative breast cancer. 
Summary of Key 
Points: 
Treatment Modalities
Invasive breast cancer is 
managed with a combination 
of surgical and systemic 
therapies: 
Lumpectomy/mastectomy 
Radiation 
Endocrine therapy
Immunotherapy
Chemotherapy 
Primary Care of Breast Cancer Survivors
Ongoing Monitoring 
Physical Examination
➢ PE every 3-6 months for the 
first 3 years following 
remission. 
➢ PE every 6-12 months for 2 
additional years. 
➢ PE annually thereafter. 
 
Imaging 
➢ Annual mammography of both 
breasts if patient has 
undergone lumpectomy or 
contralateral breast if 
mastectomy. 
➢ MRI reserved for patients at 
high risk of recurrence (>20%), 
such as those with hereditary 
cancer syndromes. 
Therapy Side Effects 
Hot flashes/ Vaginal dryness 
➢ Low estrogen as a result of 
antiestrogen hormonal therapy 
or chemotherapy-induced ovarian 
failure can lead to hot 
flashes, vaginal dryness, 
dyspareunia, and urogenital 
atrophy. 
➢ SSRIs, SNRIs, and gabapentin 
can all be used to treat hot 
flashes. 
➢ pH balanced lubricants are 
recommended for dyspareunia.  
Cardiotoxicity 
➢ Overall risk of CV disease is 
higher in patients who receive 
hormonal therapies and 
anthracyclines 
➢ Consider TTE 6-12 months after 
treatment for patients who 
receive high-dose 
anthracyclines or Trastuzumab 
Therapy Side Effects 
Decreased bone density
➢ Profound bone loss may occur 
with use of chemotherapeutic 
agents and ovarian suppression 
with AIs. 
➢ DEXA should be obtained at 
baseline and every 2 years for 
patients at risk. 
➢ Zoledronic acid and denosumab 
should be used to prevent bone 
loss in those receiving AIs. 
Lymphedema 
➢ More common for patients who 
receive ALND. 
➢ Treatment can involve a 
combination of compression 
sleeves, massage therapy, and 
physical therapy. 
Summary of Key 
Points: 
Primary Care of Breast 
Cancer Survivors 
The various therapies used 
to treat breast cancer 
have lasting effects for 
patients. Watch for: 
Hot flashes
Veginal dryness
Cardiotoxicity 
Decreased bone density
Lymphedema 
Case #2 E.S. 
Case #2: E.S. 
E.S. is a 66y/o female with PMH HTN, HLD, osteopenia who has 
received a recent diagnosis of ER+ Stage II breast cancer. 
She is particularly anxious about starting treatment and 
asks you what she can expect. 
What are you able to tell her regarding her expected 
treatment course? 
Questions? 
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